Copley Acquisition Corp

Copley Acquisition Corp (COPL) has entered into a definitive business combination agreement with Ignite Proteomics, LLC. Upon closing, Copley and Ignite will become wholly owned subsidiaries of a newly formed public holding company, Ignite Proteomics Holdings, Inc. (Pubco), which will be listed on the NYSE. The transaction values Ignite Proteomics at a $150 million pro forma enterprise value and is expected to close in the second half of 2026, subject to customary closing conditions. Clear Street LLC and Winston Taylor LLP are advising Copley, while Ladenburg Thalmann & Co. Inc. and Meister Seelig & Schuster PLLC are advising Ignite Proteomics.

Copley Acquisition Corp, a special purpose acquisition company, has entered into a definitive business combination agreement with Ignite Proteomics, a leader in pathway-level protein analytics for precision oncology. Upon closing, the combined entity will be named Ignite Proteomics Holdings, Inc. and will be listed on the New York Stock Exchange. The transaction values Ignite Proteomics at a pro forma enterprise value of $150 million and is expected to close in the second half of 2026, providing the company with a public platform and financial backing to scale its commercial infrastructure.

Copley Acquisition Corp reported a net income of $1.29 million for the three months ended March 31, 2026, a significant improvement from a loss in the prior year. However, the company's cash balance declined sharply to $4,235, and it faces a working capital deficit of $320,531. Management has raised substantial doubt about the company's ability to continue as a going concern, citing insufficient financial resources and the mandatory liquidation deadline for its SPAC operations if a business combination is not completed by May 2027.